2024年诺贝尔化学奖刚刚揭晓，美国科学家大卫·贝克（David Baker）获得了一半奖金，以表彰他在蛋白质结构设计领域所做的开创性贡献，另一半则共同授予英国科学家德米斯·哈萨比斯（Demis Hassabis）和美国科学家约翰 ·江珀（John ...

2024年诺贝尔化学奖刚刚揭晓，美国科学家大卫·贝克（David Baker）获得了一半奖金，以表彰他在蛋白质结构设计领域所做的开创性贡献，另一半则共同授予英国科学家德米斯·哈萨比斯（Demis Hassabis）和美国科学家约翰 ...

2024年诺贝尔化学奖刚刚揭晓，美国科学家大卫·贝克（David Baker）获得了一半奖金，以表彰他在蛋白质结构设计领域所做的开创性贡献，另一半则共同授予英国科学家德米斯·哈萨比斯（Demis Hassabis）和美国科学家约翰 ·江珀（John ...

Gain’s lead program in Parkinson’s disease has been awarded funding support from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and The Silverstein Foundation for Parkinson’s with GBA, ...

Vanderbilt University has synthesized metabotropic glutamate (mGlu2) receptor negative allosteric modulators reported to be useful for the treatment of depression, anxiety, Alzheimer's disease, autism ...

HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small molecule ...

BETHESDA, Md., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the ...

InnoCare Pharma has announced that its Phase II clinical study of the Tyrosine Kinase 2 (TYK2) inhibitor ICP-488 for ...

This valuable report describes the changing antiviral activity of IFIT1 across mammals and in response to distinct viruses, likely as a result of past arms races. One of the main strengths of the ...

Bad news has buffeted Sage Therapeutics Inc. twice in the past few months. Now its placebo-controlled phase II Lightwave study of dalzanemdor in Alzheimer's disease has missed the primary outcome ...

Vanqua claims VQ-101 is the first small molecule to demonstrate >75% activation of lysosomal enzyme glucocerebrosidase in ...

Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from ...